These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 29476002)

  • 1. Thymidine Metabolism as a Confounding Factor for 3'-Deoxy-3'-
    Schelhaas S; Wachsmuth L; Hermann S; Rieder N; Heller A; Heinzmann K; Honess DJ; Smith DM; Fricke IB; Just N; Doblas S; Sinkus R; Döring C; Schäfers KP; Griffiths JR; Faber C; Schneider R; Aboagye EO; Jacobs AH
    J Nucl Med; 2018 Jul; 59(7):1063-1069. PubMed ID: 29476002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3'-Deoxy-3'-18F-fluorothymidine PET for the early prediction of response to leucovorin, 5-fluorouracil, and oxaliplatin therapy in patients with metastatic colorectal cancer.
    Hong YS; Kim HO; Kim KP; Lee JL; Kim HJ; Lee SJ; Lee SJ; Oh SJ; Kim JS; Ryu JS; Moon DH; Kim TW
    J Nucl Med; 2013 Aug; 54(8):1209-16. PubMed ID: 23804324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variability of Proliferation and Diffusion in Different Lung Cancer Models as Measured by 3'-Deoxy-3'-¹⁸F-Fluorothymidine PET and Diffusion-Weighted MR Imaging.
    Schelhaas S; Wachsmuth L; Viel T; Honess DJ; Heinzmann K; Smith DM; Hermann S; Wagner S; Kuhlmann MT; Müller-Tidow C; Kopka K; Schober O; Schäfers M; Schneider R; Aboagye EO; Griffiths J; Faber C; Jacobs AH
    J Nucl Med; 2014 Jun; 55(6):983-8. PubMed ID: 24777288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine imaging.
    Moroz MA; Kochetkov T; Cai S; Wu J; Shamis M; Nair J; de Stanchina E; Serganova I; Schwartz GK; Banerjee D; Bertino JR; Blasberg RG
    Clin Cancer Res; 2011 Mar; 17(5):1099-110. PubMed ID: 21245090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Synergistic Effect of Selumetinib/Docetaxel Combination Therapy Monitored by [(18)F]FDG/[(18)F]FLT PET and Diffusion-Weighted Magnetic Resonance Imaging in a Colorectal Tumor Xenograft Model.
    Honndorf VS; Schmidt H; Wiehr S; Wehrl HF; Quintanilla-Martinez L; Stahlschmidt A; Barjat H; Emmas SA; Pichler BJ
    Mol Imaging Biol; 2016 Apr; 18(2):249-57. PubMed ID: 26276154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depicting Changes in Tumor Biology in Response to Cetuximab Monotherapy or Combination Therapy by Apoptosis and Proliferation Imaging Using
    Heinzmann K; Nguyen QD; Honess D; Smith DM; Stribbling S; Brickute D; Barnes C; Griffiths J; Aboagye E
    J Nucl Med; 2018 Oct; 59(10):1558-1565. PubMed ID: 29794225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early effects of FOLFOX treatment of colorectal tumour in an animal model: assessment of changes in gene expression and FDG kinetics.
    Strauss LG; Hoffend J; Koczan D; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2009 Aug; 36(8):1226-34. PubMed ID: 19280186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response Monitoring with [
    Heskamp S; Heijmen L; Gerrits D; Molkenboer-Kuenen JDM; Ter Voert EGW; Heinzmann K; Honess DJ; Smith DM; Griffiths JR; Doblas S; Sinkus R; Laverman P; Oyen WJG; Heerschap A; Boerman OC
    Mol Imaging Biol; 2017 Aug; 19(4):540-549. PubMed ID: 27798786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical FLT-PET and FDG-PET imaging of tumor response to the multi-targeted Aurora B kinase inhibitor, TAK-901.
    Cullinane C; Waldeck KL; Binns D; Bogatyreva E; Bradley DP; de Jong R; McArthur GA; Hicks RJ
    Nucl Med Biol; 2014 Feb; 41(2):148-54. PubMed ID: 24332383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of BIRC7/Livin, Bcl-2, p53, Annexin V, PD-L1, DARC, MSH2 and PMS2 in colorectal cancer treated with FOLFOX chemotherapy with or without aspirin.
    Faruk M; Ibrahim S; Aminu SM; Adamu A; Abdullahi A; Suleiman AM; Rafindadi AH; Mohammed A; Iliyasu Y; Idoko J; Saidu R; Randawa AJ; Musa HS; Ntekim A; Shah KZ; Abubakar S; Adoke KU; Manko M; Awasum CA
    PLoS One; 2021; 16(1):e0245581. PubMed ID: 33465114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine Mechanism of Action Confounds Early Assessment of Treatment Response by 3'-Deoxy-3'-[18F]Fluorothymidine in Preclinical Models of Lung Cancer.
    Schelhaas S; Held A; Wachsmuth L; Hermann S; Honess DJ; Heinzmann K; Smith DM; Griffiths JR; Faber C; Jacobs AH
    Cancer Res; 2016 Dec; 76(24):7096-7105. PubMed ID: 27784748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limits of [18F]-FLT PET as a biomarker of proliferation in oncology.
    McKinley ET; Ayers GD; Smith RA; Saleh SA; Zhao P; Washington MK; Coffey RJ; Manning HC
    PLoS One; 2013; 8(3):e58938. PubMed ID: 23554961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [18F]FLT PET for non-invasive assessment of tumor sensitivity to chemotherapy: studies with experimental chemotherapy TP202377 in human cancer xenografts in mice.
    Munk Jensen M; Erichsen KD; Björkling F; Madsen J; Jensen PB; Sehested M; Højgaard L; Kjær A
    PLoS One; 2012; 7(11):e50618. PubMed ID: 23226334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Prediction of Tumor Response to Treatment: Preclinical Validation of 99mTc-Duramycin.
    Elvas F; Vangestel C; Pak K; Vermeulen P; Gray B; Stroobants S; Staelens S; Wyffels L
    J Nucl Med; 2016 May; 57(5):805-11. PubMed ID: 26837335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using dual-tracer PET to predict the biologic behavior of human colorectal cancer.
    Wang H; Zhang J; Tian J; Qu B; Li T; Chen Y; Liu J; Wang S
    J Nucl Med; 2009 Nov; 50(11):1857-64. PubMed ID: 19837754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of [
    Rapic S; Vangestel C; Verhaeghe J; Thomae D; Pauwels P; Van den Wyngaert T; Staelens S; Stroobants S
    Mol Imaging Biol; 2017 Feb; 19(1):109-119. PubMed ID: 27324368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [
    Kim SY; Jung JH; Lee HJ; Soh H; Lee SJ; Oh SJ; Chae SY; Lee JH; Lee SJ; Hong YS; Kim TW; Moon DH
    Cancer Res; 2017 Dec; 77(24):7120-7130. PubMed ID: 29055019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Voxel-Based Analysis of the Relation of 3'-Deoxy-3'-[
    Schelhaas S; Frohwein LJ; Wachsmuth L; Hermann S; Faber C; Schäfers KP; Jacobs AH
    Mol Imaging Biol; 2022 Jun; 24(3):359-364. PubMed ID: 34755247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biodistribution and uptake of 3'-deoxy-3'-fluorothymidine in ENT1-knockout mice and in an ENT1-knockdown tumor model.
    Paproski RJ; Wuest M; Jans HS; Graham K; Gati WP; McQuarrie S; McEwan A; Mercer J; Young JD; Cass CE
    J Nucl Med; 2010 Sep; 51(9):1447-55. PubMed ID: 20720035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
    Barthel H; Cleij MC; Collingridge DR; Hutchinson OC; Osman S; He Q; Luthra SK; Brady F; Price PM; Aboagye EO
    Cancer Res; 2003 Jul; 63(13):3791-8. PubMed ID: 12839975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.